Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2010 Dec;19(12):1581-9. doi: 10.1517/13543784.2011.539558.

Dapagliflozin: more than just another oral glucose-lowering agent?

Author information

  • 1Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK.

Abstract

IMPORTANCE OF THE FIELD:

With current hypoglycemic therapies, only half of type 2 diabetes mellitus (T2DM) patients achieve optimal glycemic control and even fewer maintain it. Therefore, there is an unmet need for novel antidiabetic agents. Dapagliflozin, a selective inhibitor of sodium glucose transporter 2 (SGLT2), targets hyperglycemia independently of insulin, via decreasing renal glucose reabsorption.

AREAS COVERED IN THIS REVIEW:

We critically assess the results of up-to-date clinical trials with dapagliflozin in patients with T2DM and discuss its potential therapeutic applications.

WHAT THE READER WILL GAIN:

Dapagliflozin, apart from targeting hyperglycemia, also exerts beneficial effects on blood pressure, lipid profile, body weight and waist circumference. Furthermore, serum uric acid and high sensitivity C-reactive protein levels were decreased in dapagliflozin-treated patients. However, there are also potentially negative effects related to dapagliflozin use that need to be addressed, such as increased hematocrit and serum parathyroid levels and the possibility of a higher rate of urinary tract and genital infections.

TAKE HOME MESSAGE:

The use of dapagliflozin in the treatment of T2DM patients seems promising but more evidence is needed.

PMID:
21105857
DOI:
10.1517/13543784.2011.539558
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center